ストックスクリーナーアプリを入手
1.51
2.03%
0.03
アフターアワーズ：
1.55
0.04
+2.65%
Cardiff Oncology Inc (CRDF) 最新ニュース
Cardiff Oncology (CRDF) Reports Promising Phase 2 Results for On - GuruFocus
Cardiff Oncology reports positive phase 2 trial results for onvansertib - Investing.com
Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting - TradingView
New colorectal cancer drug combo shows 72% response in trial - Stock Titan
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Clinical-stage biotech CEO in Jefferies health conference fireside chat - Stock Titan
CRDF Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
CRDF Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Cardiff Oncology (CRDF) Files Lawsuit Against Nerviano Medical S - GuruFocus
TD Cowen Downgrades Cardiff Oncology to Hold From Buy - Moomoo
H.C. Wainwright cuts Cardiff Oncology stock rating on license termination By Investing.com - Investing.com Canada
TD Cowen downgrades Cardiff Oncology stock rating on license dispute By Investing.com - Investing.com Canada
Cardiff Oncology, Inc. 8-K Filing Details for May 27, 2026: Company Information, NASDAQ Listing, and Key Disclosures - Minichart
Cardiff OncologyNms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026 - TradingView
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
Cardiff Oncology 1Q Loss/Shr 18c >CRDF - Moomoo
CRDF Technical Analysis | Trend, Signals & Chart Patterns | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
CRDF: First Quarter 2026 Results - Zacks Small Cap Research
Cardiff Oncology to host webcast on cancer trial data By Investing.com - Investing.com South Africa
Cardiff Oncology to host webcast on cancer trial data - Investing.com UK
New colorectal cancer trial data heads to ASCO, investor webcast June 3 - Stock Titan
Cardiff Oncology Announces Webcast to Discuss Updated Phase - GlobeNewswire
Cardiff Oncology sues Nerviano as analyst backs Onvansertib defense - MSN
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense - Benzinga
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights - TipRanks
Cardiff Oncology, Inc. (CRDF) has filed documents with the U.S. Securities and Exchange Commission (SEC), disclosing that it has initiated a lawsuit against Nerviano Medical Sciences, accusing the latter of breaching the licensing agreement regarding the in - Bitget
Is Cardiff Oncology (CRDF) 5.1% Undervalued After Q1 2026 Earnin - GuruFocus
A Quick Look at Today's Ratings for Cardiff Oncology(CRDF.US), With a Forecast Between $6 to $10 - Moomoo
Cardiff Oncology (CRDF) Reports Positive Trial Data and Leadersh - GuruFocus
Cardiff Oncology (CRDF) Secures Funding Through 1Q27 - GuruFocus
Cardiff Oncology Q1 net loss narrows as operating expenses fall - TradingView
Cardiff Oncology earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology: Q1 Earnings Snapshot - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) details Q1 2026 loss and Phase 3 plans - Stock Titan
FDA meeting maps Phase 3 test of Cardiff's colorectal cancer drug - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) posts Q1 loss, warns on cash and details onvansertib data - Stock Titan
Cardiff Oncology, Inc.Common Stock (NQ: CRDF - FinancialContent
CRDF Stock Price, Quote & Chart | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
TradingKey - TradingKey
CRDF Technical Analysis & Stock Price Forecast - Intellectia AI
Cardiff Oncology (CRDF) to Release Earnings on Thursday - MarketBeat
MSN Money - MSN
Cardiff Oncology Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
2.89%
大文字化:
|
ボリューム (24 時間):